Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 648

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia

Open access
Bucaneve, Giampaolo, Micozzi, Alessandra, Menichetti, Francesco, Martino, Pietro, Dionisi, M. Stella, Martinelli, Giovanni, Allione, Bernardino, D'Antonio, Domenico, Buelli, Maurizio, Nosari, A. Maria, Cilloni, Daniela, Zuffa, Eliana, Cantaffa, Renato, Specchia, Giorgina, Amadori, Sergio, Fabbiano, Francesco, Deliliers, Giorgio Lambertenghi, Lauria, Francesco, Foà, Robin, Del Favero, Albano·2005·New England Journal of Medicine

Abstract

BACKGROUND: The prophylactic use of fluoroquinolones in patients with cancer and neutropenia is controversial and is not a recommended intervention. METHODS: We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia. Patients were stratified according to their underlying disease (acute leukemia vs. solid tumor or lymphoma). RESULTS: An intention-to-treat analysis showed that fever was present for the duration of neutropenia in 65 percent of patients who received levofloxacin prophylaxis, as compared with 85 percent of those receiving placebo (243 of 375 vs. 308 of 363; relative risk, 0.76; absolute difference in risk, -20 percent; 95 percent confidence interval, -26 to -14 percent; P=0.001). The levofloxacin group had a lower rate of microbiologically documented infections (absolute difference in risk, -17 percent; 95 percent confidence interval, -24 to -10 percent; P<0.001), bacteremias (difference in risk, -16 percent; 95 percent confidence interval, -22 to -9 percent; P<0.001), and single-agent gram-negative bacteremias (difference in risk, -7 percent; 95 percent confidence interval, -10 to -2 percent; P<0.01) than did the placebo group. Mortality and tolerability were similar in the two groups. The effects of prophylaxis were also similar between patients with acute leukemia and those with solid tumors or lymphoma. CONCLUSIONS: Prophylactic treatment with levofloxacin is an effective and well-tolerated way of preventing febrile episodes and other relevant infection-related outcomes in patients with cancer and profound and protracted neutropenia. The long-term effect of this intervention on microbial resistance in the community is not known.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa044097

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 648

Metadata

Authors
Bucaneve, G., Micozzi, A., Menichetti, F., Martino, P., Dionisi, M. S., Martinelli, G., Allione, B., D'Antonio, D., Buelli, M., Nosari, A. M., Cilloni, D., Zuffa, E., Cantaffa, R., Specchia, G., Amadori, S., Fabbiano, F., Deliliers, G. L., Lauria, F., Foà, R., & Del Favero, A.
Venue
New England Journal of Medicine
Published
2005-09-08
Volume
353
Issue
10
Pages
977-987
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2117158766
Cited by
648
References
17
FWCI
14.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia. https://app.cochat.ai/papers/10.1056/nejmoa044097
The paper
Bucaneve, G., Micozzi, A., Menichetti, F., Martino, P., Dionisi, M. S., Martinelli, G., Allione, B., D'Antonio, D., Buelli, M., Nosari, A. M., Cilloni, D., Zuffa, E., Cantaffa, R., Specchia, G., Amadori, S., Fabbiano, F., Deliliers, G. L., Lauria, F., Foà, R., & Del Favero, A. (2005). Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa044097

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.